- Home
- STLD vs GMAB Comparison
STLD vs GMAB Comparison
Compare STLD & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STLD
- GMAB
- Stock Information
- Founded
- STLD 1993
- GMAB 1999
- Country
- STLD United States
- GMAB Denmark
- Employees
- STLD N/A
- GMAB N/A
- Industry
- STLD Steel/Iron Ore
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- STLD Industrials
- GMAB Health Care
- Exchange
- STLD Nasdaq
- GMAB Nasdaq
- Market Cap
- STLD 20.8B
- GMAB 17.4B
- IPO Year
- STLD 1996
- GMAB N/A
- Fundamental
- Price
- STLD $154.13
- GMAB $29.19
- Analyst Decision
- STLD Buy
- GMAB Strong Buy
- Analyst Count
- STLD 9
- GMAB 7
- Target Price
- STLD $168.22
- GMAB $41.17
- AVG Volume (30 Days)
- STLD 1.3M
- GMAB 2.6M
- Earning Date
- STLD 10-20-2025
- GMAB 11-06-2025
- Dividend Yield
- STLD 1.30%
- GMAB N/A
- EPS Growth
- STLD N/A
- GMAB 77.72
- EPS
- STLD 7.51
- GMAB 21.62
- Revenue
- STLD $17,634,671,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- STLD $7.13
- GMAB $24.92
- Revenue Next Year
- STLD $8.76
- GMAB $15.97
- P/E Ratio
- STLD $20.54
- GMAB $1.35
- Revenue Growth
- STLD N/A
- GMAB 32.97
- 52 Week Low
- STLD $103.17
- GMAB $17.24
- 52 Week High
- STLD $164.73
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- STLD 55.95
- GMAB 44.71
- Support Level
- STLD $148.13
- GMAB $29.57
- Resistance Level
- STLD $164.73
- GMAB $29.39
- Average True Range (ATR)
- STLD 4.56
- GMAB 0.65
- MACD
- STLD -0.41
- GMAB -0.36
- Stochastic Oscillator
- STLD 54.47
- GMAB 21.74
About STLD Steel Dynamics Inc.
Steel Dynamics Inc operates as a domestic steel producer and metal recycler in the United States. The company's product portfolio comprises hot rolled sheet, hot rolled plate, painted sheet products, cold rolled sheet, and others. Its reportable segments are steel operations, metals recycling operations, steel fabrication operations, and aluminum operations. Maximum revenue is generated from its steel operations segment, which consists of manufacturing various steel products and numerous coating operations. Its primary sources of revenue are currently from the manufacture and sale of steel products, the processing and sale of recycled ferrous and nonferrous metals, and the fabrication and sale of steel joists and deck products.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.